Objective: To explore the clinical effect of modified Juanbitang on patients with wind-cold-wetness type rheumatoid arthritis (RA) and its effect on inflammatory factors and quality of life. Method: The 134 cases with RA treated at our hospital from January 2015 to January 2017 were selected as research objectives

and randomly divided into two groups. The same nonpharmacological treatment was provided to both groups. The control group was additionally given meloxicam+methotrexate

and the observation group was treated with modified Juanbitang. Two groups' traditional Chinese medicine (TCM) syndrome

physical and chemical indicators before and after treatment

synovial fluid inflammatory factor level

quality of life

serum matrix metalloproteinase-3 (MMP-3)

bone protection element osteoprotegerin (OPG) and receptor activator for nuclear factor-κB ligand (RANKL) expression were recorded and compared. Adverse reactions were also observed. Result: After treatment for 12 weeks

the overall effective rate of TCM syndrome in observation group was 94.0%

which was significantly higher than 82.1% in control group. The observation group was superior to control group. The two group's erythrocyte sedimentation rate erythrocyte sedimentation rate (ESR)

serum C-reactive protein (CRP)

rheumatoid factor (RF) after treatment for 12 weeks were significant lower than those before treatment (P<0.05)

and those in observation group were decreased more significantly (P<0.05). Two groups' joint fluid tumor necrosis factor (TNF)-α

and interleukin interleukin-17 (IL-17) after treatment for 12 weeks were significant lower than those before treatment (P<0.05)

and those in observation group were decreased more significantly (P<0.05). Two groups' physical component summary (PCS) and mental component summary (MCS) after treatment for 12 weeks were significant higher than those before treatment (P<0.05)

and those in observation group were increased more significantly (P<0.05). Compared with before treatment

MMP-3 and RANKL levels of two groups reduced

while OPG increased after treatment (P<0.05). Compared with control group

RANKL level of treatment group was significantly decreased after treatment

with statistically significant differences (P<0.05). Conclusion: Modified Juanbitang can relieve or eliminate the symptoms and signs of patients with wind-cold-wetness type RA

reduce the systemic inflammatory response

delay the disease progression

and improve the life quality

with a good clinical effect.